Lynparza
E505481
Lynparza is a targeted cancer therapy (a PARP inhibitor) used primarily to treat certain types of ovarian, breast, pancreatic, and prostate cancers associated with BRCA mutations.
Statements (45)
| Predicate | Object |
|---|---|
| instanceOf |
PARP inhibitor
ⓘ
drug ⓘ small molecule ⓘ targeted cancer therapy ⓘ |
| approvedBy |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| associatedWithBiomarker |
BRCA1 mutation
ⓘ
BRCA2 mutation ⓘ |
| coDevelopedBy | Merck & Co. NERFINISHED ⓘ |
| developedBy | AstraZeneca NERFINISHED ⓘ |
| dosageForm |
capsule
ⓘ
tablet ⓘ |
| firstFDAApprovalYear | 2014 ⓘ |
| hasATCCode | L01XK02 ⓘ |
| hasCommonAdverseEffect |
anemia
ⓘ
diarrhea ⓘ fatigue ⓘ nausea ⓘ vomiting ⓘ |
| hasDrugClass | poly(ADP-ribose) polymerase inhibitor ⓘ |
| hasGenericName | olaparib ⓘ |
| hasIndication |
breast cancer
ⓘ
fallopian tube cancer ⓘ ovarian cancer ⓘ pancreatic cancer ⓘ primary peritoneal cancer ⓘ prostate cancer ⓘ |
| hasIndicationDetail |
maintenance treatment of BRCA-mutated advanced ovarian cancer
ⓘ
maintenance treatment of germline BRCA-mutated metastatic pancreatic adenocarcinoma ⓘ maintenance treatment of recurrent epithelial ovarian cancer ⓘ treatment of germline BRCA-mutated, HER2-negative metastatic breast cancer ⓘ treatment of homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer ⓘ |
| hasPatentStatus | on-patent in many markets as of early 2020s ⓘ |
| hasSeriousAdverseEffect |
acute myeloid leukemia
ⓘ
myelodysplastic syndrome ⓘ pneumonitis ⓘ |
| indicationPopulation | adult patients ⓘ |
| mechanismOfAction |
induces synthetic lethality in tumor cells with BRCA mutations or homologous recombination deficiency
ⓘ
inhibits PARP enzymes involved in DNA repair ⓘ |
| metabolism | CYP3A4 ⓘ |
| pregnancyCategory | can cause fetal harm ⓘ |
| requiresCompanionDiagnostic | BRCA mutation testing for some indications ⓘ |
| routeOfAdministration | oral ⓘ |
| targets |
PARP1
NERFINISHED
ⓘ
PARP2 NERFINISHED ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.